# US 5,350,745 A · Treatment of myocardial failure

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,350,745 A
- Document ID: US5350745A
- Status: Granted
- Kind: A
- Application number: 08/010,823
- Filed: 1993-01-29
- Granted: 1994-09-27
- Earliest claimed: 1993-01-29
- Assignees: Lunar Corporation
- Inventors: Carl E. Gulbrandsen; Richard L. Moss
- Web page: https://patentgrep.com/patent/US5350745A

## CPC

- A61K 31/593: 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A61K 31/59: Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K 31/592: 9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Method of increasing the strength of contraction in the mammalian heart muscle by administering to the mammal an effective amount of an activated Vitamin D compound, i.e. a 1.alpha.-hydroxylated Vitamin D compound which binds with the Vitamin D receptor and produces a positive inotropic effect in the heart muscle. The activated Vitamin D compound may be given as a means to treat myocardial failure.

## Claims

### Claim 1

A method for preventing or treating myocardial failure in a mammal comprising administering to said mammal an effective amount of a compound of the general structure of Formula I wherein A and B are either hydrogen or a carbon to carbon bond thus forming a double bond between C22 and C23, R.sub.2, and R.sub.3 can be either hydrogen, hydroxy, lower alkyl, O-lower alkyl, O-lower acyl, O-aromatic acyl or flouro, and where R.sub.4 is hydrogen or lower alkyl along with an acceptable excipient. ##STR2##

### Claim 2 (depends on 1)

A method for treating myocardial failure as described in claim 1 wherein the compound of formula I is selected from the group consisting of 1.alpha.,25-dihydroxycholecalciferol, 1.alpha.-hydroxy-cholecalciferol, 1.alpha.,24-dihydroxy-cholecalciferol, 1.alpha.,25-dihydroxy-ergocalciferol, 1.alpha.-hydroxy-ergocalciferol, 1.alpha.,24(s)-dihydroxy-ergocalciferol, 1.alpha.,25-dihydroxy-vitamin D.sub.4, 1.alpha.-hydroxy-vitamin D.sub.4, 1.alpha.-24-dihydroxy-vitamin D.sub.4.

### Claim 3

A method for increasing the strength of the contraction in the heart of a mammal comprising administering to said mammal an effective amount of a compound of the general structure of formula I wherein A and B are either hydrogen or a carbon to carbon bond thus forming a double bond between C22 and C23, R.sub.2, and R.sub.3 can be either hydrogen, hydroxy, lower alkyl, O-lower alkyl, O-lower acyl, O-aromatic acyl or flouro, and where R.sub.4 is hydrogen or lower ##STR3## alkyl along with an acceptable excipient.

### Claim 4 (depends on 3)

A method for increasing the strength of contraction in the heart of a mammal as claimed in claim 3 wherein the compound of formula I is selected from the group consisting of 1.alpha.,25-dihydroxycholecalciferol, 1.alpha.-hydroxy-cholecalciferol, 1.alpha.,24-dihydroxy-cholecalciferol, 1.alpha.,25-dihydroxy-ergocalciferol, 1.alpha.-hydroxy-ergocalciferol, 1.alpha.,24(s)-dihydroxy-ergocalciferol, 1.alpha.,25-dihydroxy-vitamin D.sub.4, 1.alpha.-hydroxy-vitamin D.sub.4, 1.alpha.-24-dihydroxy-vitamin D.sub.4.